Effect of Gender on Coagulation Functions: A Study in Metastatic Colorectal Cancer Patients Treated with Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin
Table 1
Baseline characteristics of the groups.
Women (minimum–maximum) = 15
Men (minimum–maximum) = 19
value
Age, years
60
61.5
0.85
Colon cancer
12
14
—
Rectal cancer
3
5
—
Adenocarcinoma
15
19
Grades 1-2
5
4
Grade 3
10
15
0.4
Metastases site
Liver
8
12
Lung
1
3
Bone
3
4
0.8
Diabetes
3
4
Hypertension
2
5
1
D-dimer (mg/dL)
883 (106–2233)
794 (206–2760)
0.88
Fibrinogen (mg/dL)
382 (330–415)
348 (250–630)
0.73
aPTT (sec)
24 (19–29)
26 (19–29)
0.26
INR
0.93 (0.8–1.06)
1.0 (0.8–1.1)
0.44
Platelet count (×1000 mm3)
185 (160–274)
274 (165–468)
0.057
Hemoglobin, gr/dL
12.7 (11.9–13.3)
12.7 (10.7–16)
0.98
Creatinine, mg/dL
0.9 (0.7–1.1)
0.8 (0.5–1.1)
0.17
White blood cell, mm3
5600 (4400–13500)
6600 (3900–11000)
0.46
PFS, months
8 (6–11)
9 (4–14)
0.7
OS, months
14 (10–33)
12 (6–28)
0.044
aPTT: activated partial thromboplastin time, INR: international normalized ratio, PFS: progression-free survival, and OS: overall survival.
